Global Animal Model Market Report 2024

The animal model market size has grown strongly in recent years. It will grow from $1.76 billion in 2023 to $1.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the rising adoption of animal models for biomedical research, surging expenditure and high investments in drug development and discovery, growing focus on precision medicine, and extensive applications of animal models in the healthcare industry.

The animal model market size is expected to see strong growth in the next few years. It will grow to $2.69 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The forecast period's growth is expected to be driven by several factors, including advancements in genetic engineering techniques, a heightened emphasis on personalized medicine, the escalating prevalence of chronic diseases, the growing demand for effective vaccines and therapeutics, and increased investments in biomedical research. Anticipated trends in the forecast period include a surge in the demand for animal models in drug discovery and development efforts, driven by the need for more accurate preclinical testing. Additionally, the physiological similarities between humans and animals are expected to expedite drug development timelines. The increasing consumption of personalized medicine is projected to fuel demand for humanized mice models tailored to individual patient needs. Overall, the market is poised for significant growth due to the rising adoption of animal models for biomedical research across various sectors.

The upsurge in investment activities in pharmaceutical research and development is anticipated to drive the growth of the animal model market. Pharmaceutical research and development constitutes a multifaceted process where scientific inquiry and innovation converge to propel medical advancements. With a growing emphasis on innovative therapies targeting complex diseases, pharmaceutical R&D fuels scientific curiosity and commercial opportunities within the healthcare sector. Animal models play a pivotal role in pharmaceutical R&D by aiding in predicting drug efficacy, safety, and toxicity, offering insights into biological mechanisms, and facilitating the development of new treatments through the replication of human physiological responses and disease progression in controlled environments. For example, data from the European Federation of Pharmaceutical Industries and Associations in June 2023 revealed an increase in pharmaceutical R&D spending across Europe from €39.44 billion ($42,543 million) in 2020 to €44.5 billion ($47,999 million) in 2022, representing a 7.82% growth.

Key players in the animal model market are focusing on the development of innovative products, such as triple-immunodeficient animal models, to enhance the accuracy and reliability of preclinical studies, support advanced biomedical research, and facilitate the development of novel therapies for complex human diseases. Triple-immunodeficient animal models, typically mice, are specially engineered to lack three key immune system components, making them invaluable for studying human diseases and developing new treatments. For instance, Charles River Laboratories International, Inc., a US-based pharmaceutical company, introduced NCG mouse strains in January 2024, offering a triple-immunodeficient mouse model for oncology research. These mice lack functional/mature T, B, and NK cells, making them ideal hosts for xenograft cells, tissues, and human immune system components. NCG mice are particularly useful for research in oncology, immunology, infectious diseases, regenerative medicine, and tissue transplant studies, among others.

In October 2021, Jackson Laboratory, a US-based independent, non-profit biomedical research institution, acquired Charles River Laboratories Japan’s Research Models & Services (RMS) business for $70.9 million. This strategic acquisition aims to enhance the capabilities of Japanese researchers by providing direct access to cutting-edge animal research models, services, and scientific support. Charles River Laboratories Japan, Inc., the previous owner, was a Japan-based provider of research animal models.

Major companies operating in the animal model market are Eurofins Scientific SE, Charles River Laboratories International Inc., Pharmaron Beijing Co Ltd, Inotiv Inc., Biocytogen, Taconic Biosciences Incorporation, Cyagen Biosciences, Trans Genic Incorporation, Crown Bioscience Incorporation, Harbor BioMed, PharmaLegacy, PsychoGenics, Biomere Biomedical Research Models Inc., Genoway S.A, Alloy Therapeutics, Janvier Labs, Hera Biolabs, Ozgene Pty Ltd, Transposagen Biopharmaceuticals Inc., KMT Hepatech Inc., AniLocus Inc., BioXpert, Harlan Sprague Dawley Inc.

North America was the largest region in the animal model market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the animal model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An animal model refers to a non-human species utilized in scientific research to explore biological processes, investigate disease mechanisms, and assess the effectiveness and safety of novel treatments and interventions. These models serve as invaluable tools for advancing medical knowledge and facilitating the development of new therapies, effectively bridging the gap between fundamental research and clinical practice.

The primary types of animal models include mice, rats, guinea pigs, rabbits, hamsters, and others. Mice, for instance, are small rodents belonging to the family Muridae, typically recognized by their pointed snouts, rounded ears, and elongated, hairless tails. Technologies employed in animal modeling encompass clustered regularly interspaced short palindromic repeats (CRISPR), embryonic stem cell injection, nuclear transfer, among others, and find applications in diverse areas such as drug discovery and development, fundamental research, and more. End users of animal models include research institutes, educational institutions, pharmaceutical companies, and contract research organizations.

The animal model market research report is one of a series of new reports that provides animal model market statistics, including animal model industry global market size, regional shares, competitors with an animal model market share, detailed animal model market segments, market trends and opportunities, and any further data you may need to thrive in the animal model industry. This animal model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The animal model market consists of revenues earned by entities by providing services custom animal model development, animal breeding and colony management, behavioral and neurological testing, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The animal model market consists of sales of genetically engineered models, spontaneous models, induced models, xenograft and allograft models, and environmental models. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.